Introduction to Module 7 Case Study 1 Optimizing Cera Pediatric Drug Development
Welcome to our comprehensive guide on Module 7 Case Study 1 Optimizing Cera Pediatric Drug Development. Dr. Pascal Chanu talks about how MIDD is used to
Module 7 Case Study 1 Optimizing Cera Pediatric Drug Development Comprehensive Overview
Dr. Dinko Rekic of Astra-Zeneca shows how the FDA MIDD Pilot Program enabled a Phase 2 trial start prior to multiple standing ... Dr. Kamau Pierre, with the Translational Disease Modeling Group at Sanofi, discusses how Quantitaive Systems Pharmacology ... This
Dr. Maria Laura Sargentini-Maier with Sanofi discusses how MIDD was used to support dosing recommendations of ...
Summary & Highlights for Module 7 Case Study 1 Optimizing Cera Pediatric Drug Development
- This lecture by Dr. Rajesh Krishna is a
- Conducting clinical
- Rajesh Krishna, Senior Director with IDD Certara, reflects on how decision analysis can be used to support
- Dr. Hoai-Thu Thai with Sanofi explains how MIDD was used to support isatuximab (Sarclisa) dosing regimen selection in ...
- Dr. Binfeng Xia with Sanofi U.S. shows how Physiologically Based Pharmokinetic (PBPK) models were used to support Eliglustat ...
In summary, understanding Module 7 Case Study 1 Optimizing Cera Pediatric Drug Development gives us a better perspective.
